Last updated: July 17, 2026
Mallinckrodt Hospital Products IP Ltd. sued Praxair Distribution Inc. in 2015 over intellectual property tied to hospital delivery of nitrous oxide systems. The case is docketed as 1:15-cv-00170-GMS. The dispute centers on patent-based rights and alleged infringement tied to Praxair’s product and/or manufacturing and supply chain activities in the hospital gas space. The record includes procedural and merits activity typical of patent litigation (complaint, claim construction and motion practice, infringement and validity positions, and a final disposition). Key business takeaway: the litigation’s posture and outcome determine whether Mallinckrodt’s patent estate blocks generic entry, design-around work, or supply-chain substitution in the relevant nitrous oxide category.
What patents are asserted in Mallinckrodt Hospital Products IP Ltd. v. Praxair Distribution Inc. (1:15-cv-00170-GMS)?
Answer: The asserted patent(s) and claim(s) define the infringement map, the design-around options, and the strength of Mallinckrodt’s exclusivity.
Which patent numbers and claims drive the infringement theory?
The litigation is identified as Mallinckrodt Hospital Products IP Ltd. v. Praxair Distribution Inc., Case No. 1:15-cv-00170-GMS. The complaint and any amended pleadings typically list the asserted U.S. patent numbers and identify the accused products and conduct. The infringement analysis depends on:
- Independent claim coverage tied to apparatus/system features and/or process features
- Claim scope limits created during claim construction
- Whether the case is framed around direct infringement, induced infringement, or contributory infringement (or a combination)
How do the asserted claims map to hospital nitrous oxide delivery products?
Patent coverage in hospital nitrous oxide supply commonly turns on:
- Cylinder or bulk delivery system architecture
- Pressure regulation components
- Delivery workflows for clinical settings
- Packaging and labeling systems that align with clinical use
This matters because Praxair’s ability to design around often depends on whether the asserted claims are narrowly tied to specific structural elements versus broad functional requirements.
How does the case posture affect infringement and validity outcomes?
Answer: Procedural posture determines whether the court focuses first on claim scope (often via claim construction) or on dispositive validity/infringement motions that can end the case early.
What are the typical key milestones in this case?
Patent disputes at this stage usually include:
- Pleadings: complaint, answer, and any amended complaint
- Rule-based motion practice (dismissal and pleadings sufficiency)
- Claim construction briefing and hearings
- Summary judgment motions (infringement and/or invalidity)
- Final judgment or settlement disposition
What is the likely legal framing: injunction vs. damages?
The business impact differs depending on the relief sought:
- If Mallinckrodt pursued an injunction, the case becomes leverage-centric around market exclusivity
- If Mallinckrodt pursued damages only, settlement often becomes more favorable for both sides when design-around is feasible
What validity challenges does Praxair raise in response to Mallinckrodt’s asserted patents?
Answer: Validity positions typically target novelty, obviousness, and written description/enablement. The strongest defense strategy uses prior art that narrows claim scope or anticipates the accused product.
Obviousness and anticipation are usually the core
In patent litigation involving product systems in established gas delivery markets, the most common arguments are:
- Anticipation by earlier patents or published materials on hospital gas delivery components
- Obviousness based on combinations of prior art components
- Challenges to whether the specification supports the breadth Mallinckrodt claims during infringement
How does claim construction change validity odds?
If claim construction narrows the relevant limitation (for example, a specific structural arrangement or pressure regulation feature), Praxair’s prior art mapping can fail. If the limitation stays broad, anticipation and obviousness become more plausible.
What does the claim construction likely do to the infringement analysis?
Answer: Claim construction defines the “working” scope of what Praxair must avoid. It determines which features in Praxair’s system are material, and which are irrelevant.
Structural limitations vs. functional limitations
Patent estates in delivery systems often mix:
- Structural limitations (specific components, configurations, or interfaces)
- Functional limitations (what the system achieves under clinical use)
Structural limitations favor design-around because Praxair can swap components. Functional limitations can be harder to work around if Praxair’s product still performs the same function with equivalent structures.
How does the court’s construction affect “literal infringement” versus “equivalents”?
If the court narrows terms tightly, Mallinckrodt may need to rely on doctrine of equivalents to catch design-around variants. Praxair’s risk increases if the asserted claims remain broad enough to cover minor variations.
What products and conduct are accused in the Praxair infringement theory?
Answer: The accused products and conduct are typically tied to the delivery system and supply of nitrous oxide in hospital settings. The infringement case usually distinguishes:
- The manufactured hardware
- The distributed configuration
- The clinical deployment workflow
Direct infringement and “system” coverage
If the asserted claims cover a “system” used in clinical settings, Mallinckrodt often argues that Praxair sells a complete system or sells components that together meet each claim limitation.
Induced or contributory infringement risks
If Mallinckrodt frames liability around how Praxair sells or markets the system for clinical use, Praxair’s exposure increases when the evidence supports:
- Knowledge of infringement
- Intentional facilitation of the infringing combination
What is the litigation outcome and what does it mean for Mallinckrodt’s market position?
Answer: The outcome determines whether Mallinckrodt retains enforceable leverage over hospital nitrous oxide delivery systems and whether Praxair can continue sales without licensing.
Judgment and remedies
Patent cases typically conclude with:
- A final judgment after dispositive motions
- A settlement with licensing terms or business restrictions
- A consent judgment tied to non-infringement, invalidity, or design-around
The remedy sought shapes commercial effect:
- An injunction would block specific product configurations
- Damages support licensing valuation
- A settlement can define acceptable substitutes and future manufacturing constraints
What settlement, licensing, or stipulations are relevant to business decisions?
Answer: Settlement terms govern the effective “future exclusivity” even after the formal case ends. They can:
- License the accused technology
- Allow continued sales under specified configurations
- Impose design-around obligations for later versions
What do settlement terms usually specify in hospital delivery system cases?
Business-critical provisions usually include:
- Licensed claims and excluded configurations
- Duration and territory
- Royalties or lump-sum payments
- “No further claims” and cross-licenses
- Quality/manufacturing standards affecting redesign feasibility
How strong is Mallinckrodt’s patent estate in this litigation?
Answer: Strength is determined by:
- Claim construction outcomes that preserve core limitations
- Validity survival against obviousness/anticipation attacks
- Evidence of infringement that ties specific product features to each claim limitation
Indicators of enforceability
Mallinckrodt’s enforceability risk rises if:
- The asserted claims are narrowed heavily by construction
- The accused product lacks one crucial limitation
- Prior art fills the gap after construction
Mallinckrodt’s enforceability risk falls if:
- Claims survive construction broad enough to cover Praxair’s design
- Prior art mapping fails to anticipate key elements
What generic or “design-around” entry risks exist for Praxair’s substitutes?
Answer: The entry risk is a function of what the patents actually cover and whether design-around can be achieved without triggering equivalents.
Where design-around is most feasible
Design-around is feasible when asserted coverage focuses on:
- Specific structures that can be replaced
- Specific component geometry that can be reconfigured
Where design-around is hardest
Design-around is harder when coverage is broad or functional, especially if the system’s clinical performance and integration remain the same.
How does this case affect competitive landscape among hospital gas suppliers?
Answer: The litigation affects competitor behavior by clarifying:
- Which design choices trigger infringement
- Whether licensing is required to supply certain hospital system configurations
- Whether the market expects design-around adoption or licensing
Competitive spillover
Even absent an injunction, a high-risk patent finding can push suppliers toward:
- Product redesign
- Contractual licensing
- Supply-chain sourcing changes
Key Takeaways
- Case identity: Mallinckrodt Hospital Products IP Ltd. v. Praxair Distribution Inc., 1:15-cv-00170-GMS (Docketed in federal court).
- IP focus: The dispute targets patent rights tied to hospital gas delivery systems for nitrous oxide.
- Business leverage: Outcome and any settlement define whether Praxair must license, redesign, or face restrictions.
- Infringement hinge: Claim construction and the mapping of each accused feature to each claim limitation drive the merits.
- Entry risk: Design-around feasibility depends on whether the asserted claims require specific structural components versus broad functional integration.
FAQs
-
Does this case involve Paragraph IV-type issues or Orange Book exclusivity?
This dispute is not an FDA Orange Book exclusivity framework case; it is a patent infringement action tied to hospital product technology.
-
How do claim construction results affect Praxair’s ability to redesign?
Narrow constructions typically reduce literal coverage and increase the importance of doctrine-of-equivalents arguments.
-
What evidence matters most for system “use in hospitals” infringement theories?
Evidence that ties sold configurations, deployment instructions, and integration in clinical settings to each claim limitation.
-
If a settlement occurs, can other gas suppliers use the same workaround?
Other suppliers can copy the design-around only to the extent it avoids the licensed/excluded claim scope and any stipulated configuration limits.
-
What litigation posture most impacts licensing valuation?
Whether the court grants dispositive rulings on infringement or validity, and whether any settlement includes claim coverage and royalty/license terms.
References
- Public docket for Mallinckrodt Hospital Products IP Ltd. v. Praxair Distribution Inc., Case No. 1:15-cv-00170-GMS.
